727 related articles for article (PubMed ID: 29419429)
21. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
22. Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.
Finnes HD; Chaffee KG; Call TG; Ding W; Kenderian SS; Bowen DA; Conte M; McCullough KB; Merten JA; Bartoo GT; Smith MD; Leis J; Chanan-Khan A; Schwager SM; Slager SL; Kay NE; Shanafelt TD; Parikh SA
Leuk Lymphoma; 2017 Jun; 58(6):1376-1383. PubMed ID: 27820970
[TBL] [Abstract][Full Text] [Related]
23. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Titus-Rains KS; Brown JN; Hammond JM
J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
[TBL] [Abstract][Full Text] [Related]
24. A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib.
Mato AR; Tang B; Azmi S; Yang K; Zhang X; Stern JC; Hedrick E; Huang J; Sharman JP
Haematologica; 2022 Nov; 107(11):2630-2640. PubMed ID: 35443563
[TBL] [Abstract][Full Text] [Related]
25. Severe arthritic syndrome due to ibrutinib use for chronic lymphocytic leukemia.
Dasanu CA
J Oncol Pharm Pract; 2019 Jun; 25(4):1003-1005. PubMed ID: 29720040
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.
Mato AR; Nabhan C; Barr PM; Ujjani CS; Hill BT; Lamanna N; Skarbnik AP; Howlett C; Pu JJ; Sehgal AR; Strelec LE; Vandegrift A; Fitzpatrick DM; Zent CS; Feldman T; Goy A; Claxton DF; Bachow SH; Kaur G; Svoboda J; Nasta SD; Porter D; Landsburg DJ; Schuster SJ; Cheson BD; Kiselev P; Evens AM
Blood; 2016 Nov; 128(18):2199-2205. PubMed ID: 27601462
[TBL] [Abstract][Full Text] [Related]
27. Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.
Moldovianu AM; Stoia R; Vasilica M; Ursuleac I; Badelita SN; Tomescu AA; Preda OD; Bardas A; Cirstea M; Coriu D
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837525
[No Abstract] [Full Text] [Related]
28. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Bitar C; Farooqui MZ; Valdez J; Saba NS; Soto S; Bray A; Marti G; Wiestner A; Cowen EW
JAMA Dermatol; 2016 Jun; 152(6):698-701. PubMed ID: 26982511
[TBL] [Abstract][Full Text] [Related]
29. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes.
Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P
Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508
[TBL] [Abstract][Full Text] [Related]
30. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.
Gordon MJ; Jones JE; George B; Peterson C; Burger JA; Jain N; Keating M; Wierda WG; Durand JB; Ferrajoli A
Cancer; 2023 Jul; 129(14):2192-2200. PubMed ID: 37016930
[TBL] [Abstract][Full Text] [Related]
32. Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.
Kipps TJ; Fraser G; Coutre SE; Brown JR; Barrientos JC; Barr PM; Byrd JC; O'Brien SM; Dilhuydy MS; Hillmen P; Jaeger U; Moreno C; Cramer P; Stilgenbauer S; Chanan-Khan AA; Mahler M; Salman M; Eckert K; Solman IG; Balasubramanian S; Cheng M; Londhe A; Ninomoto J; Howes A; James DF; Hallek M
Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):715-722.e6. PubMed ID: 31447270
[TBL] [Abstract][Full Text] [Related]
33. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Ryan CE; Sahaf B; Logan AC; O'Brien S; Byrd JC; Hillmen P; Brown JR; Dyer MJ; Mato AR; Keating MJ; Jaglowski S; Clow F; Rezvani AR; Styles L; Coutre SE; Miklos DB
Blood; 2016 Dec; 128(25):2899-2908. PubMed ID: 27802969
[TBL] [Abstract][Full Text] [Related]
34. Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.
Mato AR; Samp JC; Gauthier G; Terasawa E; Brander DM
Cancer Biol Ther; 2018 Jul; 19(7):636-643. PubMed ID: 29584544
[TBL] [Abstract][Full Text] [Related]
35. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
[TBL] [Abstract][Full Text] [Related]
36. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Tran PN; O'Brien S
Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
[TBL] [Abstract][Full Text] [Related]
37. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
[TBL] [Abstract][Full Text] [Related]
38. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
Molica S
Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
[TBL] [Abstract][Full Text] [Related]
39. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
[TBL] [Abstract][Full Text] [Related]
40. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
Jain P; Keating M; Wierda W; Estrov Z; Ferrajoli A; Jain N; George B; James D; Kantarjian H; Burger J; O'Brien S
Blood; 2015 Mar; 125(13):2062-7. PubMed ID: 25573991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
